Clinical efficacy of atezolizumab plus bevacizumab for the treatment of advanced hepato-cellular carcinoma
10.3760/cma.j.cn115610-20210703-00327
- VernacularTitle:阿替利珠单克隆抗体联合贝伐珠单克隆抗体治疗晚期肝细胞癌的临床疗效
- Author:
Min LI
1
;
Shasha FAN
;
Wei PENG
;
Yichao CHEN
;
Yao ZHANG
;
Huaxin DUAN
Author Information
1. 湖南师范大学附属第一医院（湖南省人民医院）肿瘤一科，长沙 410005
- Keywords:
Liver neoplasms;
Immunotherapy;
Atezolizumab;
Bevacizumab;
Esopha-geal varices
- From:Chinese Journal of Digestive Surgery
2021;20(S2):29-31
- CountryChina
- Language:Chinese
-
Abstract:
Results of the IMbrave150 clinical study showed that atezolizumab plus bevaci-zumab have better overall survival and progression-free survival than sorafenib in the treatment of hepatocellular carcinoma patients. However, hepatocellular carcinoma patients with esophageal varices were not included in the IMbrave150 clinical study mainly considering the bleeding risk of patients undergoing treatment of bevacizumab. The authors introduce the atezolizumab plus bevaci-zumab treatment of an advanced hepatocellular carcinoma patient with moderate esophageal varices. By reducing the dose of bevacizumab, the patient achieved an excellent curative effect.
